Patents by Inventor Beth Ann Strifler

Beth Ann Strifler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pan-ELR+ CXC chemokine antibodies
    Patent number: 10858425
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: December 8, 2020
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • Pan-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20180362631
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 20, 2018
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • Pan-ELR+ CXC chemokine antibodies
    Patent number: 10093727
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: October 9, 2018
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher, Sudhakar Reddy Chintharlapalli
  • Pan-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20170362315
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: September 5, 2017
    Publication date: December 21, 2017
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • Pan-ELR CXC chemokine antibodies
    Patent number: 9783605
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: October 10, 2017
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Derrick Ryan Witcher, Beth Ann Strifler
  • PAN-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20160152699
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: February 3, 2016
    Publication date: June 2, 2016
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Derrick Ryan Witcher, Beth Ann Strifler
  • Pan-ELR+ CXC Chemokine Antibodies
    Patent number: 9290570
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: March 22, 2016
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • Pan-ELR+ CXC CHEMOKINE ANTIBODIES
    Publication number: 20140271647
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Applicant: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
  • MUTEINS OF FIBROBLAST GROWTH FACTOR 21
    Publication number: 20090118190
    Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
    Type: Application
    Filed: January 6, 2009
    Publication date: May 7, 2009
    Inventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
  • Muteins of fibroblast growth factor 21
    Patent number: 7491697
    Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: February 17, 2009
    Assignee: Eli Lilly and Company
    Inventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
  • Human phospholipase A.sub.2 and related nucleic acid compounds
    Patent number: 6103510
    Abstract: The invention provides a novel phospholipase A.sub.2 enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: August 15, 2000
    Assignee: Eli Lilly and Company
    Inventors: Ruth Maria Kramer, Richard Todd Pickard, John David Sharp, Beth Ann Strifler